3Stratton IM,Adler AI, Neil HA,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes ( UKPDS 35 ) : prospective observational study [J]. BMJ, 2000, 321:405 - 412.
4Jinping Weng,Yanbing Li,Wen Xu,et al. Effect of intensive insulin therapy on β-cell function and glyeaemic conronl in patients with newly diagnosed type 2 diahetes:a muhicentrntre randomized parallel-group trial[J]. Lancet, 2008,371 (9626) : 1577 - 1580.
5Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Comolications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [J]. N Engl J Med, 2005, 353:2643-2653.
6Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes[J]. N Eng J Med , 2008, 359(5): 1577 - 1589.
7Gaede P,Lund-Andersen H ,Paving HH,et al. Effect of a muhifaetorial intervention on mortality in type 2 diabetes [J]. N Engl J Med, 2008, 358:580 -591.
8Alraira C, Duckworth WC, Moriz T, et al. Glycaemic separation and risk factor control in the Veterans Affaris Diabetes Trial:an interm report[ J ]. Diabetes Obes Metab, 2009, 11 (2) : 150 - 156.
9Kingry C, Bastien A,Booth G, et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Dibetes (ACCORD) trial [J]. Am J Cardiol,2007,99: 68i - 79i.
10CHEATHAM W W.Repaglinide-prandial glucose regulator: a new class of oral diabetic drugs[J].Diabet Med,1998,15(suppl):28-36.
6American Diabtes Association. Diagnosis and classification of dia- betes mellitus. Diabetes Care,2004,27 (suppll) :5-10.
7Nathan DM, Buse JB, Davidson MB, et al. Management of hyper- glycemia in type 2 diabetes : a consensus algorithm for the initia- tion and adjustment of therapy:a consensus statement from the A- merican Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care,2008,31 ( 1 ) :173-175.
